Recent Updates
Recently added Catalysts
BLTE Positive Sentiment Score: 70/100

Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference

Tuesday, May 14, 2024 1 min read
Key Takeaway: Belite Bio, Inc. (NASDAQ: BLTE) has announced its participation in the Benchmark's 4th Annual Healthcare House Call Investor Conference, which will take place virtually on May 21 and 22, 2024. The company's executive management will host a fireside chat at 3:00 pm ET on May 21. This event underscores Belite Bio's commitment to addressing the needs in the field of degenerative retinal diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Belite Bio is actively engaging with investors at a major conference.
  • The participation includes a fireside chat, indicating a proactive communication strategy.
  • The focus on novel therapeutics for retinal diseases highlights the company's innovative approach.

Full Press Release Details

SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference being held virtually on May 21 and 22, 2024. The Company will host a fireside chat at 3:00 pm ET on May 21, 2024.
Media and Investor Relations Contact:
belite@argotpartners.com

Frequently Asked Questions

What company is participating in the Healthcare House Call?

Belite Bio, Inc. is participating in the conference.

When will the conference take place?

The conference is scheduled for May 21 and 22, 2024.

What time is Belite's fireside chat?

Belite's fireside chat is at 3:00 pm ET on May 21, 2024.

What is Belite Bio focused on?

Belite Bio focuses on developing therapies for degenerative retinal diseases.

How can investors contact Belite Bio?

Investors can contact Belite at belite@argotpartners.com.

Tags: BLTE Viatris Investor Conferences Healthcare Belite Bio degenerative retinal diseases investor conference biopharmaceuticals
Last updated: May 14, 2024